# Cryopreservation and transplantation of ovarian tissue as post-cancer tissue therapy and an activator of oogenesis

## TL;DR

This paper argues that ovarian tissue cryopreservation is beneficial for cancer patients by acting as tissue therapy and promoting egg development.

## Contribution

The paper introduces two new arguments for ovarian tissue cryopreservation: tissue therapy and activation of oogenesis.

## Key findings

- Cryopreserved ovarian tissue transplantation can act as a tissue therapy for post-cancer patients.
- Ovarian tissue cryopreservation activates oogenesis in post-cancer patients.
- Germinal vesicle oocytes retrieved during tissue dissection can be matured and used in IVF.

## Abstract

In a recent publication (Reprod. Biomed. Online, 2024) it was presented point of view that, for post-cancer patients, in vitro fertilization (IVF) is a more effective method than ovarian tissue cryopreservation (OTC). In their commentary, Andersen et al. (Reprod. Biomed. Online, 2024) present nine distinct arguments advocating for the use of OTC. We fully agree with all these points. In support of the clinical application of the OTC procedure, we introduce two additional arguments. First, the transplantation of cryopreserved ovarian tissue can be considered as a form of tissue therapy. Moreover, OTC inherently serves as an activator of oogenesis. Second, during tissue dissection prior to OTC, a significant number of germinal vesicle (GV) oocytes can be retrieved, matured to the metaphase II (MII) stage, cryopreserved, and later used in IVF procedures.